Acute Leukemias IV: Prognostic Factors and Treatment Strategies
The rates of acute leukemia cure have gradually improved over the last decade. Clinical study results reflect the impact of chemotherapy intensity and duration, the role of prolonged maintenance, intensified consolidation or very early intensification. Further progress has also been achieved in bone...
Gespeichert in:
| Weitere Verfasser: | , , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
1994
|
| Schriftenreihe: | Haematology and Blood Transfusion Hämatologie und Bluttransfusion
36 |
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | The rates of acute leukemia cure have gradually improved over the last decade. Clinical study results reflect the impact of chemotherapy intensity and duration, the role of prolonged maintenance, intensified consolidation or very early intensification. Further progress has also been achieved in bone marrow trans plantation, and recent prospective studies and meta-analyses have contributed comparisons of the high antileukemic efficacy of bone marrow transplantation to that of improved chemotherapy. This allows a more successful combining of the two forms of treatment. New prognostic factors have emerged from both cytogenetic and molecular genetic research. Thus, the Philadelphia chromosome translocation and the bcr/abl gene rearrangement have proven to be the dominating risk factor in acute lymphoblastic leukemia. Since the frequency increases with age, differences in prognosis between children and adults can be explained. Evaluation of molecular and immunologic leukemia cell markers has provided a better understanding of residual leukemia in clinical remission, as a prognostic factor and in monitoring the effectiveness of the antileukemic strategy. Recent work on leukemic cell biology has resulted in novel therapeutic approaches such as terminal differentiation by all-trans-retinoic acid, modulation of chemotherapy by hematopoietic growth factors such as GM-CSF and enhancement of immunologic control by cytokines such as interleukin 2. New antimicrobial drugs and the application of mostly empiric anti-infectious strategies have helped reducing the therapeutic risk. Thus, a number of recent achievements have provided us with new options in the management of patients with acute leukemias |
| Beschreibung: | 1 Online-Ressource (XXXVI, 803 p) |
| ISBN: | 9783642783500 |
| DOI: | 10.1007/978-3-642-78350-0 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046143468 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1994 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642783500 |9 978-3-642-78350-0 | ||
| 024 | 7 | |a 10.1007/978-3-642-78350-0 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-642-78350-0 | ||
| 035 | |a (OCoLC)1119001682 | ||
| 035 | |a (DE-599)BVBBV046143468 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.15 |2 23 | |
| 245 | 1 | 0 | |a Acute Leukemias IV |b Prognostic Factors and Treatment Strategies |c edited by T. Büchner, W. Hiddemann, B. Wörmann, G. Schellong, J. Ritter |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 1994 | |
| 300 | |a 1 Online-Ressource (XXXVI, 803 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Haematology and Blood Transfusion Hämatologie und Bluttransfusion |v 36 | |
| 520 | |a The rates of acute leukemia cure have gradually improved over the last decade. Clinical study results reflect the impact of chemotherapy intensity and duration, the role of prolonged maintenance, intensified consolidation or very early intensification. Further progress has also been achieved in bone marrow trans plantation, and recent prospective studies and meta-analyses have contributed comparisons of the high antileukemic efficacy of bone marrow transplantation to that of improved chemotherapy. This allows a more successful combining of the two forms of treatment. New prognostic factors have emerged from both cytogenetic and molecular genetic research. Thus, the Philadelphia chromosome translocation and the bcr/abl gene rearrangement have proven to be the dominating risk factor in acute lymphoblastic leukemia. Since the frequency increases with age, differences in prognosis between children and adults can be explained. Evaluation of molecular and immunologic leukemia cell markers has provided a better understanding of residual leukemia in clinical remission, as a prognostic factor and in monitoring the effectiveness of the antileukemic strategy. Recent work on leukemic cell biology has resulted in novel therapeutic approaches such as terminal differentiation by all-trans-retinoic acid, modulation of chemotherapy by hematopoietic growth factors such as GM-CSF and enhancement of immunologic control by cytokines such as interleukin 2. New antimicrobial drugs and the application of mostly empiric anti-infectious strategies have helped reducing the therapeutic risk. Thus, a number of recent achievements have provided us with new options in the management of patients with acute leukemias | ||
| 650 | 4 | |a Hematology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Pediatrics | |
| 650 | 4 | |a Hematology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Pediatrics | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 700 | 1 | |a Büchner, T. |4 edt | |
| 700 | 1 | |a Hiddemann, W. |4 edt | |
| 700 | 1 | |a Wörmann, B. |4 edt | |
| 700 | 1 | |a Schellong, G. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642783524 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540569510 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642783517 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-78350-0 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031523653 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-642-78350-0 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180477558390784 |
|---|---|
| any_adam_object | |
| author2 | Büchner, T. Hiddemann, W. Wörmann, B. Schellong, G. |
| author2_role | edt edt edt edt |
| author2_variant | t b tb w h wh b w bw g s gs |
| author_facet | Büchner, T. Hiddemann, W. Wörmann, B. Schellong, G. |
| building | Verbundindex |
| bvnumber | BV046143468 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-642-78350-0 (OCoLC)1119001682 (DE-599)BVBBV046143468 |
| dewey-full | 616.15 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.15 |
| dewey-search | 616.15 |
| dewey-sort | 3616.15 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-642-78350-0 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03578nmm a2200517zcb4500</leader><controlfield tag="001">BV046143468</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1994 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642783500</subfield><subfield code="9">978-3-642-78350-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-78350-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-642-78350-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119001682</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046143468</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.15</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Acute Leukemias IV</subfield><subfield code="b">Prognostic Factors and Treatment Strategies</subfield><subfield code="c">edited by T. Büchner, W. Hiddemann, B. Wörmann, G. Schellong, J. Ritter</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XXXVI, 803 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Haematology and Blood Transfusion Hämatologie und Bluttransfusion</subfield><subfield code="v">36</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The rates of acute leukemia cure have gradually improved over the last decade. Clinical study results reflect the impact of chemotherapy intensity and duration, the role of prolonged maintenance, intensified consolidation or very early intensification. Further progress has also been achieved in bone marrow trans plantation, and recent prospective studies and meta-analyses have contributed comparisons of the high antileukemic efficacy of bone marrow transplantation to that of improved chemotherapy. This allows a more successful combining of the two forms of treatment. New prognostic factors have emerged from both cytogenetic and molecular genetic research. Thus, the Philadelphia chromosome translocation and the bcr/abl gene rearrangement have proven to be the dominating risk factor in acute lymphoblastic leukemia. Since the frequency increases with age, differences in prognosis between children and adults can be explained. Evaluation of molecular and immunologic leukemia cell markers has provided a better understanding of residual leukemia in clinical remission, as a prognostic factor and in monitoring the effectiveness of the antileukemic strategy. Recent work on leukemic cell biology has resulted in novel therapeutic approaches such as terminal differentiation by all-trans-retinoic acid, modulation of chemotherapy by hematopoietic growth factors such as GM-CSF and enhancement of immunologic control by cytokines such as interleukin 2. New antimicrobial drugs and the application of mostly empiric anti-infectious strategies have helped reducing the therapeutic risk. Thus, a number of recent achievements have provided us with new options in the management of patients with acute leukemias</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pediatrics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pediatrics</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Büchner, T.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hiddemann, W.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wörmann, B.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schellong, G.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642783524</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540569510</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642783517</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-78350-0</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031523653</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-78350-0</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Konferenzschrift |
| id | DE-604.BV046143468 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:23Z |
| institution | BVB |
| isbn | 9783642783500 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031523653 |
| oclc_num | 1119001682 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XXXVI, 803 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1994 |
| publishDateSearch | 1994 |
| publishDateSort | 1994 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| series2 | Haematology and Blood Transfusion Hämatologie und Bluttransfusion |
| spelling | Acute Leukemias IV Prognostic Factors and Treatment Strategies edited by T. Büchner, W. Hiddemann, B. Wörmann, G. Schellong, J. Ritter Berlin, Heidelberg Springer Berlin Heidelberg 1994 1 Online-Ressource (XXXVI, 803 p) txt rdacontent c rdamedia cr rdacarrier Haematology and Blood Transfusion Hämatologie und Bluttransfusion 36 The rates of acute leukemia cure have gradually improved over the last decade. Clinical study results reflect the impact of chemotherapy intensity and duration, the role of prolonged maintenance, intensified consolidation or very early intensification. Further progress has also been achieved in bone marrow trans plantation, and recent prospective studies and meta-analyses have contributed comparisons of the high antileukemic efficacy of bone marrow transplantation to that of improved chemotherapy. This allows a more successful combining of the two forms of treatment. New prognostic factors have emerged from both cytogenetic and molecular genetic research. Thus, the Philadelphia chromosome translocation and the bcr/abl gene rearrangement have proven to be the dominating risk factor in acute lymphoblastic leukemia. Since the frequency increases with age, differences in prognosis between children and adults can be explained. Evaluation of molecular and immunologic leukemia cell markers has provided a better understanding of residual leukemia in clinical remission, as a prognostic factor and in monitoring the effectiveness of the antileukemic strategy. Recent work on leukemic cell biology has resulted in novel therapeutic approaches such as terminal differentiation by all-trans-retinoic acid, modulation of chemotherapy by hematopoietic growth factors such as GM-CSF and enhancement of immunologic control by cytokines such as interleukin 2. New antimicrobial drugs and the application of mostly empiric anti-infectious strategies have helped reducing the therapeutic risk. Thus, a number of recent achievements have provided us with new options in the management of patients with acute leukemias Hematology Oncology Pediatrics Oncology (DE-588)1071861417 Konferenzschrift gnd-content Büchner, T. edt Hiddemann, W. edt Wörmann, B. edt Schellong, G. edt Erscheint auch als Druck-Ausgabe 9783642783524 Erscheint auch als Druck-Ausgabe 9783540569510 Erscheint auch als Druck-Ausgabe 9783642783517 https://doi.org/10.1007/978-3-642-78350-0 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Acute Leukemias IV Prognostic Factors and Treatment Strategies Hematology Oncology Pediatrics Oncology |
| subject_GND | (DE-588)1071861417 |
| title | Acute Leukemias IV Prognostic Factors and Treatment Strategies |
| title_auth | Acute Leukemias IV Prognostic Factors and Treatment Strategies |
| title_exact_search | Acute Leukemias IV Prognostic Factors and Treatment Strategies |
| title_full | Acute Leukemias IV Prognostic Factors and Treatment Strategies edited by T. Büchner, W. Hiddemann, B. Wörmann, G. Schellong, J. Ritter |
| title_fullStr | Acute Leukemias IV Prognostic Factors and Treatment Strategies edited by T. Büchner, W. Hiddemann, B. Wörmann, G. Schellong, J. Ritter |
| title_full_unstemmed | Acute Leukemias IV Prognostic Factors and Treatment Strategies edited by T. Büchner, W. Hiddemann, B. Wörmann, G. Schellong, J. Ritter |
| title_short | Acute Leukemias IV |
| title_sort | acute leukemias iv prognostic factors and treatment strategies |
| title_sub | Prognostic Factors and Treatment Strategies |
| topic | Hematology Oncology Pediatrics Oncology |
| topic_facet | Hematology Oncology Pediatrics Oncology Konferenzschrift |
| url | https://doi.org/10.1007/978-3-642-78350-0 |
| work_keys_str_mv | AT buchnert acuteleukemiasivprognosticfactorsandtreatmentstrategies AT hiddemannw acuteleukemiasivprognosticfactorsandtreatmentstrategies AT wormannb acuteleukemiasivprognosticfactorsandtreatmentstrategies AT schellongg acuteleukemiasivprognosticfactorsandtreatmentstrategies |